Boehringer's Ofev, Roche's Esbriet win same-day IPF approvals
This article was originally published in Scrip
The FDA played no favorites in the idiopathic pulmonary fibrosis (IPF) space – approving two new medicines on the same day on 15 October for the fatal lung disease, Boehringer Ingelheim's Ofev (nintedanib) and Roche's Esbriet (pirfenidone), despite the different timelines the drugs were on for the agency's nod.
You may also be interested in...
Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts. At BIO, he outlined his strategy and goals.